Mendus-Enrollment completed in phase 1b CML trial-07/08/2026

Research evidence excerpt

Mendus-Enrollment completed in phase 1b CML trial-07/08/2026

Mendus

NEWSFLASH | 8 JUL 2026

Enrollment completed in phase 1b CML trial

Mendus announced completion of enrollment for the first stage of the VITAL-CML trial (NCT07651878), which comprises 8

chronic myeloid leukemia (CML) patients with suboptimal TKI response. The investigator-led phase 1b trial tests whether

vididencel can safely deepen molecular responses, potentially qualifying patients for treatment-free remission. Initial safety

and early efficacy data are expected in 2H 2026, with an additional 16 patients planned to be recruited. Positive results would

enable further phase 2a development in CML.

Chien-Hsun Lee

+41 445 51 3822, chien-hsun.lee@paretosec.com

For disclosures on relevant definitions, methods, risks, potential conflicts of interests etc. and disclaimers please see www.paretosec.com. Investment Recommendations should be reviewed in

conjunction with the information therein. When distributed in the US: This document is intended for institutional investors and is not subject to all of the independence and disclosure standards

applicable to equity/debt research reports prepared for retail investors. This material is considered by Pareto Securities to qualify as an acceptable minor non-monetary benefit according to Directive

2014/65/EU Article 24 (7)(8) and Commission Delegated Directive 2017/593.

Pareto Securities © 2026 1